Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy
G. Stynes(GlaxoSmithKline (United Kingdom)), Scott Berry(Queen's University), E Castelnuovo(GlaxoSmithKline (United Kingdom)), David Leather(GlaxoSmithKline (United Kingdom)), Jaro Wex(GlaxoSmithKline (United Kingdom)), Michelle A. Detry(Berry & Associates (United States)), Sally Lettis(GlaxoSmithKline (United Kingdom)), Henrik Svedsäter(GlaxoSmithKline (United Kingdom))
Cited by 13
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951